Espoo, 15 February 2022 – Nordic BioTech Group Ltd, marketed as NordShield® ("NordShield®") is pleased to announce signing a distribution agreement for its long-lasting disinfectant series NordShield® Brilliant with MEPHARMA Consultancy DWC LLC ("MEPHARMA")
MEPHARMA will be promoting and distributing the unique, wood-extract based NordShield® Brilliant series, and thus bringing a new kind of disinfectant to its markets. The distribution agreement signed with MEPHARMA covers nine markets: United Arab Emirates, Qatar, Jordan, Saudi-Arabia, Kuwait, Egypt, Morocco, Bahrain, and Oman. This agreement and the added nine countries bring the number of countries where NordShield® Brilliant is offered to a total of 25.
The NordShield® Brilliant series has three products on the market:
· Brilliant Surfaces for hard surfaces,
· Brilliant Hands for hand disinfection and
· Brilliant Fresh for shoes, performance gear and feet for odor control
Before the market entry of NordShield® Brilliant products, disinfectants have generally been based on ethanol as the active substance to eliminate germs. The effect of ethanol is short-lived, and after it has evaporated, typically in a matter of seconds, the treated surface is exposed to contamination again. NordShield® Brilliant products contain ethanol for the immediate kill effect; however, the long-lasting protection of the surface is derived from its disruptive technology based on the unique layer that does not evaporate but forms a durable physical, armor-like barrier on the treated surface. Thus, upon application, the unique barrier formulation of NordShield® Brilliant technology provides both an immediate kill and sustained protection of surfaces against microbes. The duration can vary based on the surface and the strain on it. The entire NordShield® Brilliant series has received the 3-star quality seal and rating "excellent" in dermatological tests conducted by renowned Dermatest GmbH in Germany.
"We are delighted to be represented by MEPHARMA in these significant markets. They have an excellent reputation and track record, and I am assured that this is only the beginning of a long and fruitful collaboration for both parties."
- Kristoffer Ekman, CEO of NordShield®
"We are proud to be bringing this unique, Nordic technology to our markets and being able to provide a truly different and sustainable alternative to current solutions. We look forward to a long collaboration that has already started very strong."
- Dr. Ayman Mahmoud, CEO of MEPHARMA
MEPHARMA is a consulting firm established in 2019 specializing in providing various services to the life sciences firms in the Regulatory Affairs, Medical Affairs, Pharmacovigilance, Market Access, Quality Assurance and Compliance as well sales and marketing that of interest of biotech, pharmaceutical and other potential companies in the MENA region. We deliver clever insights and focused actions that transform into sustainable business success.
For more information, visit www.mepharma.ae
Contact to MEPHARMA:
Ayman Mahmoud, Managing Director
Nordic BioTech Group, branded as NordShield®, is the world-leading innovative biotechnology company in developing new bio-based antimicrobial solutions. Founded in 2016 and headquartered in Espoo, Finland, NordShield® is disrupting the field of antimicrobial technology through a durable, wood-based alternative for antimicrobial surface protection utilized across applications and industries. NordShield®, as a commercial technology, was born after more than ten years of researching, developing, testing, verifying, certifying, and patenting. The result is a revolutionary technology with a unique combination of naturality, power and efficacy. This scalable technology enables the strongest protection with the highest innovativeness - a creation as unique and powerful as nature and one that leaves nothing but goodness behind.
For more information, visit www.nordshield.com
Contact to NordShield®:
Emmi Kavander, Chief Communications Officer
This document may contain statements related to Nordic Biotech Group Ltd's future business and financial performance and future events or developments that may constitute forward-looking statements. Nordic BioTech Group Oy does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated status of any such statements. Nordic Biotech Group neither intends nor assumes any obligation to update or revise these statements in light of developments that differ from those anticipated. Nordic BioTech Group Oy and its affiliates are not liable for any decision made or action taken in conjunction with the information and/or statement in this document or for any related damage.
This document contains statements that are only applicable within the European Union, and this document is intended only for distribution within the European Union. Nordic BioTech Group Oy does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of any such statements and is not liable for any such statements.